Drug Class:
anthracyclines and related substances

PharmGKB contains no dosing guidelines for this drug class. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this drug class. To report a drug label with PGx, click here.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs1001179 -262, -330C>T, 34400231C>T, 34460231C>T, 4760C>T, CAT -262C > T, CAT:
C > T
5' Flanking
No VIP available CA VA
rs10426377 21360452C>A, 378+1540C>A, 41806C>A, 423+1540C>A, 49092234C>A
C > A
Intronic
rs1045642 208920T>A, 208920T>C, 25171488A>G, 25171488A>T, 3435T>A, 3435T>C, 87138645A>G, 87138645A>T, ABCB1*6, ABCB1: 3435C>T, ABCB1: C3435T, ABCB1: c.3435C>T, ABCB1:3435C>T, Ile1145=, Ile1145Ile, MDR1 3435C>T, MDR1 C3435T, PGP C3435T, c.3435C>T, mRNA 3853C>T
A > T
A > G
Synonymous
Ile1145Ile
No VIP available CA VA
rs1056892 23180577G>A, 37518706G>A, 730G>A, 93-53C>T, CBR3 730G>A, CBR3 V244M, CBR3:Val244Met, Val244Met
G > A
Intronic
Val244Met
No VIP available CA VA
rs10836235 34400704C>T, 34460704C>T, 5233C>T, 66+78C>T, CAT c.66 + 78C > T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs1149222 1119+403C>A, 25106618G>T, 40974C>A, 87073775G>T
G > T
Intronic
No VIP available CA VA
rs1736557 171080080G>A, 22568722G>A, 25063G>A, 769G>A, Val257Met
G > A
Missense
Val257Met
No VIP available CA VA
rs17583889 138746039C>A, 191-12449C>A, 28494702C>A, 29232C>A
C > A
Intronic
No VIP available No Clinical Annotations available VA
rs17645700 138780932T>C, 28529595T>C
T > C
Not Available
No VIP available No Clinical Annotations available VA
rs17863783 -7-168G>T, 108888G>T, 234602277G>T, 548536G>T, 627G>T, 855+10839G>T, 855+20842G>T, 855+56254G>T, 856-73403G>T, Val209=
G > T
Intronic
Val209Val
No VIP available No Clinical Annotations available VA
rs1800566 20389C>T, 23359344G>A, 445C>T, 457C>T, 559C>T, 69745145G>A, NQO1*2, NQO1:C609T, NQO1:P187S, NQO1:c.558C>T, Pro149Ser, Pro153Ser, Pro187Ser, rs1800566 C>T
G > A
Missense
Pro149Ser
No VIP available No Clinical Annotations available VA
rs2019604 1176382T>G, 1664-1137T>G, 45961T>G, 89615765T>G
T > G
Intronic
No VIP available No Clinical Annotations available VA
rs2020870 107A>G, 171154959A>G, 22643601A>G, Asp36Gly
A > G
Missense
Asp36Gly
No VIP available CA VA
rs2032582 186947T>A, 186947T>G, 25193461A>C, 25193461A>T, 2677A, 2677G, 2677T, 2677T>A, 2677T>G, 3095G>T/A, 87160618A>C, 87160618A>T, 893 Ala, 893 Ser, 893 Thr, ABCB1*7, ABCB1: 2677G>T/A, ABCB1: 2677T/A>G, ABCB1: A893S, ABCB1: G2677T/A, ABCB1: c.2677G>T/A, ABCB1:2677G>A/T, ABCB1:2677G>T/A, ABCB1:A893T, Ala893Ser/Thr, MDR1, MDR1 G2677T/A, Ser893Ala, Ser893Thr, mRNA 3095G>T/A, p.Ala893Ser/Thr
A > C
A > T
Missense
Ser893Ala
Ser893Thr
No VIP available No Clinical Annotations available VA
rs2108623 16017006G>A, 7279808G>A
G > A
Not Available
No VIP available CA VA
rs2232228 22757776A>G, 279A>G, 69143577A>G, Ala93=
A > G
Synonymous
Ala93Ala
No VIP available No Clinical Annotations available VA
rs2235047 209033T>G, 25171375A>C, 3489+59T>G, 87138532A>C
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs2290271 413162A>C, 603+166A>C, 85447635A>C
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs2305364 417802T>C, 795+249T>C, 85452275T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs316019 160670282A>C, 64839739A>C, 808T>G, SLC22A2: A270S, SLC22A2: Ala270Ser, Ser270Ala
A > C
Missense
Ser270Ala
No VIP available No Clinical Annotations available VA
rs4148350 132044G>T, 16110477G>T, 16170477G>T, 1988+219G>T
G > T
Intronic
No VIP available No Clinical Annotations available VA
rs4148808 -852A>G, 25138638T>C, 87105795T>C, 8954A>G
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs4261716 234593117G>T, 539376G>T, 855+11682G>T, 855+1679G>T, 855+47094G>T, 855+65909G>T, 99728G>T
G > T
Intronic
No VIP available No Clinical Annotations available VA
rs4877847 16110949A>C, 206+9072T>G, 60+9072T>G, 86946417A>C
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs4880 160113872A>G, 47C-T, 47T>C, 5482T>C, 64283329A>G, Ala16Val, SOD1:Val16Ala, SOD2: Val16Ala, T47C, V16A
A > G
Missense
Val16Ala
No VIP available CA VA
rs6759892 -7-776T>G, 108280T>G, 19T>G, 234601669T>G, 547928T>G, 855+10231T>G, 855+20234T>G, 855+55646T>G, 856-74011T>G, Ser7Ala
T > G
Intronic
Ser7Ala
No VIP available CA VA
rs729147 *1038C>T, 100333267G>A, 24880988G>A
G > A
3' Flanking
No VIP available CA VA
rs7319981 103723722G>A, 16813398G>A, 475C>T
G > A
Not Available
No VIP available CA VA
rs7853758 1381C>T, 16065458G>A, 1703C>T, 86900926G>A, Leu461=
G > A
Not Available
Leu461Leu
No VIP available CA VA
rs885004 1184-360C>T, 16074082G>A, 862-360C>T, 86909550G>A
G > A
Intronic
No VIP available CA VA
rs9024 *133G>A, 23107184G>A, 37445313G>A, 377+1866C>T, CBR1:1096G>A
G > A
3' UTR
No VIP available CA VA
rs9514091 103714254G>A, 16803930G>A, 378-3522C>T, 9943C>T
G > A
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Generic Names
Trade Names
Brand Mixture Names

PharmGKB Accession Id:
PA130620651

Other Vocabularies

Drugs And Small Molecules

The following have been classified under this therapeutic category:

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

No related drugs are available.

Curated Information ?

Publications related to anthracyclines and related substances: 24

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hyaluronan Synthase 3 Variant and Anthracycline-Related Cardiomyopathy: A Report From the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014. Wang Xuexia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The expression profile of ATP-binding cassette transporter genes in breast carcinoma. Pharmacogenomics. 2013. Hlaváč Viktor, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2013. Relling Mary V, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics. 2011. Giovannetti Elisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes--A report From the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. Blanco Javier G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. Visscher Henk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. The pharmacogenomics journal. 2010. Gréen H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. Pharmacogenomics. 2010. Hammer Christian, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British journal of cancer. 2010. Bray J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. The pharmacogenomics journal. 2010. Cizmarikova M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leukemia & lymphoma. 2009. Rajić Vladan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. Advanced drug delivery reviews. 2009. Marsh Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer research. 2009. DeMichele Angela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug metabolism and disposition: the biological fate of chemicals. 2009. Bains Onkar S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2009. Chang H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008. Blanco Javier G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenetics and genomics. 2008. Maggini Valentina, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer science. 2008. Lal Suman, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. International journal of cancer. Journal international du cancer. 2006. Kim Dong Hwan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005. Wojnowski Leszek, et al. PubMed
Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. International journal of oncology. 2003. Kafka Ariane, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics. 2002. Blanco Javier G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1999. Legrand O, et al. PubMed

Clinical Trials

These are trials that mention anthracyclines and related substances and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.